Correction to: Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

1. The results of a 24-month controlled, prospective study of relapsing multiple sclerosis patients at risk for progressive multifocal encephalopathy, who switched from prolonged use of natalizumab to teriflunomide.Multiple sclerosis journal - experimental, translational and clinical · 2021
   Article
2. [Initial ophthalmic manifestation of a fatal underlying disease : Importance of perimetry in unspecific visual deterioration].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2021
   Article

Corrections and comments

• Erratum for
  Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event.2018

Authors and funding

5 authors at 3 institutions in 3 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract